公开(公告)号：US12036389B2

公开(公告)日：2024-07-16

申请号：US17142425

申请日：2021-01-06

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Yibin Zheng ,  Jason O'Connor

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2205/52 ,  A61M2230/201

Abstract: Exemplary embodiments provide an approach to predicting meal and/or exercise events for an insulin delivery system that otherwise does not otherwise identify such events. The insulin delivery system may use a model of glucose insulin interactions that projects estimated future glucose values based on a history of glucose values and insulin deliveries for a user. The predictions of meal events and/or exercise events may be based on residuals between actual glucose values and predicted glucose values. The exemplary embodiments may calculate a rate of change of the residuals over a period of time and compare the rate of change to thresholds to determine whether there likely has been a meal event or an exercise event. The insulin delivery system may then take measures to account for the meal event or the exercise event by the user.

公开(公告)号：US11439754B1

公开(公告)日：2022-09-13

申请号：US17539270

申请日：2021-12-01

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Yibin Zheng ,  Jason O'Connor ,  Ashutosh Zade

IPC: A61M5/172 ,  A61M5/142 ,  G16H20/17

Abstract: Disclosed herein is a method for execution by a drug delivery device for determining an optimal dose of a liquid drug for current cycle of a medication delivery algorithm, the method utilizing a stepwise evaluation of a model and a cost function across a coarse search space consisting of coarse discrete quantities of the drug and a refined search space consisting of refined discrete quantities of the drug.

公开(公告)号：US12121701B2

公开(公告)日：2024-10-22

申请号：US17582349

申请日：2022-01-24

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Jason O'Connor ,  Yibin Zheng ,  Ashutosh Zade

IPC: G16H20/17 ,  A61B5/00 ,  A61B5/145 ,  A61K38/22 ,  A61K38/26 ,  A61K38/28 ,  A61M5/14 ,  A61M5/142 ,  A61M5/172 ,  G16H40/67

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  A61B5/4839 ,  A61B5/4866 ,  A61B5/7282 ,  A61K38/22 ,  A61K38/26 ,  A61K38/28 ,  A61M5/1408 ,  A61M5/14248 ,  G16H20/17 ,  G16H40/67 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/8206 ,  A61M2230/201

Abstract: Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.

公开(公告)号：US11935637B2

公开(公告)日：2024-03-19

申请号：US16586499

申请日：2019-09-27

Applicant: INSULET CORPORATION

Inventor： Joon Bok Lee ,  Yibin Zheng ,  Jason O'Connor ,  Trang Ly ,  Eric Benjamin

IPC: G16H20/17 ,  A61M5/172 ,  G16H40/67

CPC classification number: G16H20/17 ,  A61M5/1723 ,  G16H40/67 ,  A61M2205/18 ,  A61M2205/3584 ,  A61M2205/505 ,  A61M2230/201

Abstract: Disclosed are a device, a computer-readable medium, and techniques that provide an onboarding process and an adaptivity process for a drug delivery device. A processor executing an onboarding process determines whether a history of delivered insulin to a user meets certain sufficiency requirements. The onboarding process enables a processor to cause the drug delivery device to administer doses of insulin to a user according to an initial total daily insulin dose calculation that is determined based on the sufficiency of the insulin delivery history. The initial total daily insulin may be adapted according to the adaptivity process as new insulin delivery is collected. The insulin delivery history, when sufficient, may be used to set total daily insulin dosages that enable automated insulin delivery upon replacement of a drug delivery device. The adaptivity process may be implemented to modify an initial insulin delivery doses to provide adapted insulin delivery doses.

公开(公告)号：US11607493B2

公开(公告)日：2023-03-21

申请号：US16840483

申请日：2020-04-06

Applicant: INSULET CORPORATION

Inventor： Joon Bok Lee ,  Mengdi Li ,  Jason O'Connor ,  Yibin Zheng

IPC: G08B1/08 ,  A61M5/172 ,  G16H20/17 ,  G16H40/67 ,  G16H50/50 ,  G16H10/40 ,  G16H10/60 ,  G16H50/30 ,  G16H50/70 ,  G16H50/20 ,  H04L67/141

Abstract: Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.

公开(公告)号：US11324889B2

公开(公告)日：2022-05-10

申请号：US16791648

申请日：2020-02-14

Applicant: Insulet Corporation

Inventor： Yibin Zheng ,  Joon Bok Lee ,  Ashutosh Zade ,  Jason O'Connor

IPC: A61M5/172 ,  G06F17/17

Abstract: Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.

公开(公告)号：US10716896B2

公开(公告)日：2020-07-21

申请号：US15359187

申请日：2016-11-22

Applicant: INSULET CORPORATION

Inventor： Jason O'Connor ,  Daniel Allis ,  David Nazzaro ,  John R. Bussiere ,  John D'Arco

IPC: A61M5/172 ,  G16H40/63 ,  G16H20/17 ,  A61M5/142 ,  G06F19/00

Abstract: Systems and methods for automatically delivering medication to a user. A sensor coupled to a user can collect information regarding the user. A controller can use the collected information to determine an amount of medication to provide the user. The controller can instruct a drug delivery device to dispense the medication to the user. The drug delivery device can be a wearable insulin pump that is directly coupled to the user. The controller can be part of or implemented in a cellphone. A user can be required to provide a confirmation input to allow a determined amount of insulin to be provided to the user based on detected glucose levels of the user. The sensor, controller, and drug delivery device can communicate wirelessly.

公开(公告)号：US12097352B2

公开(公告)日：2024-09-24

申请号：US17412729

申请日：2021-08-26

Applicant: Insulet Corporation

Inventor： Jason O'Connor ,  Matthew Alles ,  Robert Sanzone ,  Craig Brodeur ,  Joseph Melo ,  Christopher Williams ,  Noel Schaeffer

IPC: A61M5/142

CPC classification number: A61M5/14244 ,  A61M2005/14208 ,  A61M2005/14252 ,  A61M2205/18 ,  A61M2205/3327 ,  A61M2205/3553 ,  A61M2205/50 ,  A61M2205/581 ,  A61M2205/584

Abstract: The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal-only dosing of insulin. In a primary embodiment, the wearable drug delivery device is configured to provide automatic operation and provides audible alerts and visual status indicators to the patient. In other embodiments, the patient may have some degree of control over the operation of the device by providing tapping gestures on housing of the device. In yet another embodiment, the patient may provide input and receive status from the device via an application executing on a portable computing device in wireless communication with the wearable drug delivery device.

公开(公告)号：US12090301B2

公开(公告)日：2024-09-17

申请号：US16404456

申请日：2019-05-06

Applicant: Insulet Corporation

Inventor： Jason O'Connor ,  Joon Bok Lee ,  Trang Ly ,  Yibin Zheng ,  Thomas Arnold Peyser ,  Jennifer Lena Schneider

IPC: A61M5/172 ,  A61B5/00 ,  A61B5/145 ,  A61M5/142 ,  A61M5/145

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  A61M5/14244 ,  A61M5/145 ,  A61B5/486 ,  A61B5/6832 ,  A61M2005/14208 ,  A61M2005/14252 ,  A61M2205/18 ,  A61M2205/52 ,  A61M2230/201

Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.

公开(公告)号：US11986630B2

公开(公告)日：2024-05-21

申请号：US16788892

申请日：2020-02-12

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Ashutosh Zade ,  Jason O'Connor ,  Trang Ly ,  Yibin Zheng ,  Connor Gullifer ,  Kyle Grover

IPC: A61M5/172 ,  G16H20/17

CPC classification number: A61M5/1723 ,  G16H20/17 ,  A61M2202/07 ,  A61M2205/18 ,  A61M2205/3569 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/581 ,  A61M2205/583 ,  A61M2230/201

Abstract: The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.